Improved Cognitive Function
The cognitive-enhancement properties of Gingko together with the properties of the PEA and caffeine induce, potentially, a broad spectrum of activities affecting multiple neuronal networks.*
Cogniben™ is the first multi-target modulator for cognitive support.*
Figure I: Effect of 1 week treatment with PEA, Ginkgo, and Caffeine on PEA urine levels in adult subjects with attention and focus issues. Administration of the ingredient combination found in Cogniben™ and its effect on Urine PEA levels.
The synergistic blend and ratio of ingredients in Cogniben™ are key to its demonstrated efficacy.* When combined with PEA, Ginkgo may markedly improve PEA bioavailability (figure 1) and efficacy (figure 2).* The combined cognitive support properties, neuronal network modulation activity, and stimulating effects of Cogniben’s™ ingredients induce a broad spectrum of benefits in a relatively short period of time, potentially expanding support options for cognitive issues.* The importance of the dopaminergic, serotonergic, cholinergic, and adrenergic neuronal networks in supporting those with cognitive disorders is supported by significant clinical research.*
Safety and Efficacy of Cogniben™ on Adults with Symptions of Cognitive Impairment.
Figure 2. Safety and Efficacy of Cogniben™ on Adults with Symptoms of Cognitive Impairment.
Dosing was titrated from half tablet Cogniben™ daily on Day 0 to tablets daily on Day 14 and maintained for an additional 5 weeks. A 42-percent reduction in the Average Symptom Score was observed over the course of the seven-week study.
A recent single-blind, dose titration, outpatient study evaluated the efficacy of Cogniben™ on 10 adults (18-55 years) with symptoms of cognitive impairment. Subjects were titrated from half tablet of Cogniben™ daily, up to the maximal does of two tablets per day by the end of the 2nd week. This dose was maintained for an additional 5 weeks. Subjects’ symptoms, well-being, and improvements were assessed via questionnaires at baseline and subsequent visits.
The primary efficacy endpoint was the average change from baseline to endpoint in total average symptom score.*